Merck & Company (MRK)

Healthcare · Drug Manufacturers - General · S&P 500
$141.94 +1.72% on the day Market cap $353.0B 52-week range $82.01 to $156.92 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
10% a year for 10 years

At a market value of $353.0B, Merck & Company's free cash flow of $12.4B (fiscal 2025) would need to grow about 10% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Merck & Company's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price9.7% a year
Free cash flow, last 9 years3.9% a year
Revenue, same period5.6% a year
Price to free cash flow28.6x

Fundamental grade

D

Five factors scored 1 to 9 from MRK's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability4
Growth2
Financial health2
Cash efficiency7

Key numbers

P/E (trailing)40.3x
P/E (forward)27.6x
Price / free cash flow28.6x
EV / EBITDA35.7x
Price / sales5.30x
Price / book7.50x
Revenue growth+5.1%
Operating margin—
Net margin4.8%
Return on equity7.6%
Dividend yield2.3%
Debt / equity2.09x

Results from SEC filings

Fiscal years, from Merck & Company's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$48.7B$59.3B$60.1B$64.2B$65.0B
Net income$13.0B$14.5B$365M$17.1B$18.3B
Free cash flow$8.7B$14.7B$9.1B$18.1B$12.4B
EPS (diluted)$5.14$5.71$0.14$6.74$7.28
Operating margin—————

Where the revenue comes from

Revenue by segments, fiscal 2025.

Pharmaceutical segment$58.1B90%
Animal Health$6.4B10%

Superinvestors who own MRK

From each investor's latest 13F filing (what a 13F shows). 17 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Bill Nygren
Harris Associates LP
Trimmed $1.6B2.1%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $1.0B0.36%Q2 2026
Bill Smead
Smead Capital Management
Trimmed $300M6.4%Q2 2026
Charles Brandes
Brandes Investment Partners, LP
Trimmed $246M1.7%Q2 2026
Hersh Cohen
ClearBridge Investments
Trimmed $73M0.06%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $68M0.16%Q2 2026
Thomas Kahn
Kahn Brothers Group
Trimmed $28M4.4%Q2 2026
Tom Steyer
Farallon Capital Management LLC
Trimmed $26M0.12%Q2 2026
Prem Watsa
Fairfax Financial Holdings
Held $22M0.84%Q2 2026
Dodge & Cox
Dodge & Cox
Trimmed $17M0.01%Q2 2026
Mario Gabelli
GAMCO Investors
Trimmed $8M0.07%Q2 2026
PRIMECAP Management
PRIMECAP Management Co
Trimmed $5M0.00%Q2 2026

Insider buying

Open-market purchases by Merck & Company's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 10, 2026 Ro Khanna
0$117.14—
Mar 10, 2026 Ro Khanna
0$117.14—
Feb 4, 2026 Josh Gottheimer
0$118.35—
Feb 4, 2026 Josh Gottheimer
0$118.35—
Dec 19, 2025 Gilbert Ray Cisneros, Jr.
0$100.92—
Dec 19, 2025 Gilbert Ray Cisneros, Jr.
0$100.92—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$96.61—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$96.61—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when MRK trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Merck & Company's stock price imply?

At a market value of $353.0B, Merck & Company would need its free cash flow to grow about 10% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 4% a year.

Are Merck & Company insiders buying the stock?

8 open-market insider purchases of MRK in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Merck & Company?

17 of the superinvestors Investingly tracks hold MRK in their latest 13F, including Bill Nygren, Cliff Asness, Bill Smead.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.